MOTIVATION LETTER The National Consortium on Alcohol and Neurodevelopment in Adolescence Data Analysis Resource represents the exact intersection of computational pharmacology and developmental neuroscience where my independent research operates. My Conjunctive Consolidation Threshold model, a tripartite pharmacological framework for reward-memory encoding prevention, was validated through ODE/RK45 and Bayesian MCMC methods showing an encoding probability reduction from 0.855 to 0.122, an 85.8 percent decrease with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed. This framework directly addresses the mechanisms by which alcohol reinforces maladaptive reward-memory consolidation during adolescence, a period when the developing brain exhibits heightened vulnerability to substance-induced neuroadaptations. My Bayesian population dynamics architecture, specified in the preprint on Zenodo (10.5281/zenodo.20492472), provides a formal mathematical infrastructure for analyzing longitudinal neurodevelopmental data. The model treats reward-memory consolidation thresholds as latent variables that shift with repeated alcohol exposure, age, and neurodevelopmental stage. Applied to NCANDA data, this approach could identify subpopulations of adolescents whose consolidation thresholds cross critical boundaries during specific developmental windows, enabling targeted intervention timing. Nigeria has one of the highest rates of adolescent alcohol initiation in West Africa, with limited longitudinal neuroimaging infrastructure. My position as an independent researcher in Lagos, building computational platforms such as IMPRINT for addiction-liability screening and TOPOLOGIX for topological data analysis of drug-protein interactions, demonstrates that high-resolution computational neuroscience can originate from LMIC settings. The provisional patent on CCT core architecture filed in Q3 2026 protects the framework for potential clinical translation. Endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard who provided my arXiv endorsement, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU confirm that the CCT model engages with the leading theoretical frameworks in computational psychiatry. My review article under consideration at Neuroscience and Biobehavioral Reviews synthesizes the CCT model within the broader reward-memory literature. I am not eligible for this specific U24 continuation grant as it is limited to the current NCANDA Data Analysis Resource awardee. However, I am positioning the CCT framework and Bayesian population dynamics pipeline as a novel analytical resource for future NCANDA-related funding opportunities. The model is fully specified, mathematically formalized, and ready for application to existing longitudinal datasets. I seek to establish a collaboration pathway that brings computational pharmacology from Lagos into the NCANDA consortium infrastructure. RESEARCH STATEMENT The Conjunctive Consolidation Threshold model addresses a fundamental gap in alcohol neurodevelopment research: the absence of a formal mathematical framework that predicts when and how adolescent alcohol exposure converts transient reward signals into persistent memory traces that drive addiction. Current models treat reward-memory encoding as a binary event. The CCT model specifies three pharmacological parameters that must simultaneously cross a conjunctive threshold for encoding to occur: dopamine D1 receptor activation magnitude, NMDA receptor-mediated calcium influx duration, and protein synthesis-dependent synaptic tagging kinetics. Each parameter is modeled as a continuous variable with age-dependent baseline values derived from developmental neurobiology literature. The formal mathematical specification, deposited at OSF (10.17605/OSF.IO/EMY4U), defines the conjunctive threshold as a three-dimensional manifold in parameter space. Encoding occurs only when all three parameters exceed their respective critical values simultaneously. The Bayesian population dynamics extension, published on Zenodo (10.5281/zenodo.20492472), treats individual variation in these parameters as hierarchical random effects, enabling inference at both group and individual levels. Validation used ODE/RK45 numerical integration with 10,000 parameter combinations drawn from prior distributions informed by human pharmacological data. The 85.8 percent reduction in encoding probability under combined pharmacological blockade represents the model's central prediction: super-additive efficacy arises from the conjunctive architecture itself, not from additive effects of individual drug actions. For adolescent alcohol research, the model generates specific testable predictions. First, adolescents aged 14-17 should show lower conjunctive thresholds than adults aged 25-35 due to elevated baseline D1 receptor density in the prefrontal cortex during this developmental window. Second, binge alcohol exposure should transiently lower the NMDA receptor parameter threshold through ethanol-induced NMDA receptor upregulation, creating a 24-72 hour window of increased encoding vulnerability. Third, individual differences in the protein synthesis-dependent tagging parameter, which is genetically influenced through BDNF Val66Met polymorphism, should predict differential susceptibility to alcohol-cue memory formation. These predictions can be tested against existing NCANDA longitudinal data on alcohol use patterns, neuroimaging measures of striatal and prefrontal activation, and behavioral measures of cue reactivity. The computational infrastructure for testing these predictions is already built. IMPRINT screens addiction liability from pharmacological profiles using the CCT parameter space. TOPOLOGIX applies persistent homology and bipartite simplicial complexes to drug-protein interaction networks, with a validated hERG cardiotoxicity MVP. GATE evaluates BCI neural-stimulation safety under Apache 2.0 license. All platforms run on Python with scipy, numpy, PyMC for Bayesian inference, and Gudhi for topological data analysis. The pipeline is containerized for Nextflow and SLURM HPC environments, making it portable to any institutional computing infrastructure. The LMIC perspective is not incidental. Adolescent alcohol use in Nigeria occurs in contexts of limited mental health infrastructure, high stigma, and minimal pharmacological intervention options. The CCT model identifies specific molecular targets for prevention that could be deployed as low-cost, single-dose interventions during critical developmental windows. This translational pathway from computational model to field-deployable prevention strategy is the long-term objective. CAREER DEVELOPMENT PLAN My immediate goal is enrollment in an MSc program in Computational Neuroscience or Neuropharmacology starting October 2026, with applications submitted to Medical University of Graz and University of Graz in Austria. The MSc will provide formal training in advanced neuroimaging analysis, electrophysiological data processing, and clinical trial design that my independent research has not yet covered. Specifically, I need supervised experience in fMRI preprocessing pipelines, EEG/MEG source localization, and longitudinal mixed-effects modeling for clinical datasets. The CCT model requires validation against human neuroimaging data. NCANDA datasets contain the exact variables needed: longitudinal alcohol use measures, structural and functional MRI, and behavioral assessments of reward processing and impulse control. My Bayesian population dynamics framework is designed to ingest such data. The MSc thesis will apply the CCT model to a publicly available adolescent alcohol dataset, testing the three developmental predictions specified in the research statement. This work will be submitted for publication in Biological Psychiatry or Neuropsychopharmacology. Concurrent with MSc training, I will pursue three specific skill-building objectives. First, completion of the Neuromatch Academy computational neuroscience course to strengthen neural network modeling skills. Second, a summer internship at a laboratory using rodent models of adolescent alcohol exposure, such as the laboratory of Dr. Fulton Crews at UNC Chapel Hill or Dr. Linda Spear at Binghamton University, to gain hands-on experience with the behavioral pharmacology that grounds the CCT model's parameters. Third, training in advanced Bayesian methods through the Stan conference or the PyMC educational series, specifically hierarchical modeling for multi-site neuroimaging data. The long-term career trajectory targets an independent research position at a Nigerian university or research institute, establishing the first computational neuroscience laboratory focused on addiction in sub-Saharan Africa. Nigeria has no dedicated computational neuroscience PhD program. I will build one. The CCT model, IMPRINT platform, and TOPOLOGIX infrastructure form the core intellectual property and computational tools for this laboratory. The provisional patent filed in Q3 2026 protects the commercial pathway for clinical translation. Funding for the MSc and subsequent PhD will come from a combination of LMIC-track fellowships, DAAD scholarships, and the Wellcome Trust Early Career Award scheme. My eligibility for early-career, pre-PhD, and LMIC-specific programmes is established. The endorsements from Berridge, Gershman, Daw, and Mattar provide the reference network required for competitive applications. Within five years, the objective is to have the CCT model validated against at least two independent longitudinal datasets, the IMPRINT platform deployed in at least three Nigerian clinical settings for addiction-liability screening, and a formal collaboration agreement with the NCANDA consortium for data analysis contributions. The Bayesian population dynamics pipeline will be published as an open-source R and Python package, enabling other researchers to apply the CCT framework to their own datasets. CHECKLIST - [ ] Confirm eligibility: verify that the U24 continuation grant is indeed limited to current NCANDA Data Analysis Resource awardee and that no exceptions exist for new investigators - [ ] Prepare one-page summary of CCT model for NCANDA consortium director, Dr. Sandra Brown, with specific data analysis proposals - [ ] Update ORCID profile (0009-0001-9272-6735) with all three preprints and review article status - [ ] Request letters of support from Kent Berridge, Samuel Gershman, Nathaniel Daw, and Marcelo Mattar - [ ] Prepare budget justification for MSc tuition, living expenses, and computational infrastructure - [ ] Draft data use agreement request for NCANDA public-use datasets - [ ] Verify that the Bayesian population dynamics preprint on Zenodo (10.5281/zenodo.20492472) includes complete code and data for reproducibility - [ ] Prepare biosketch following NIH format, emphasizing independent research productivity without formal graduate training - [ ] Identify alternative funding mechanisms: NIAAA R36 dissertation award, F31 diversity fellowship, Wellcome Trust Early Career Award, DAAD research grant - [ ] Submit application to Medical University of Graz MSc program by October 2026 deadline EDITOR NOTES - Eligibility is the primary risk. The U24 continuation grant is explicitly limited to the current awardee. This application functions as a capability demonstration and relationship-building document, not a fundable submission. The applicant must confirm this interpretation with the NIH program officer before investing further time. - The review article under review at Neuroscience and Biobehavioral Reviews needs a status update. If accepted by the application deadline, include the citation. If still under review, note the journal and submission date. - The provisional patent filing in Q3 2026 is listed as a future event. Verify the exact filing date and patent office. If not yet filed, adjust the timeline or remove the claim. - The endorsements from Berridge, Gershman, Daw, and Mattar should be confirmed in writing. A single sentence email from each confirming they have reviewed the CCT model and support the applicant's career development would suffice for the application. - The applicant's age (29) and gap between B.Pharm graduation (2021) and current independent research (2025-2026) should be addressed briefly in the career development plan. Frame the intervening years as deliberate preparation for computational research, including the bioinformatics role at GHRU-GSAR and the CDDDP docking research.